Free Trial
NASDAQ:KALV

KalVista Pharmaceuticals (KALV) Stock Price, News & Analysis

KalVista Pharmaceuticals logo
$11.15 -0.39 (-3.38%)
Closing price 04/1/2025 04:00 PM Eastern
Extended Trading
$11.22 +0.07 (+0.67%)
As of 04/1/2025 06:35 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About KalVista Pharmaceuticals Stock (NASDAQ:KALV)

Key Stats

Today's Range
$11.02
$11.78
50-Day Range
$8.56
$12.60
52-Week Range
$7.30
$15.50
Volume
831,980 shs
Average Volume
386,737 shs
Market Capitalization
$554.33 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$24.83
Consensus Rating
Buy

Company Overview

KalVista Pharmaceuticals, Inc., a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of drug therapies inhibitors for diseases with unmet needs. The company's product candidate is Sebetralstat, a small molecule plasma kallikrein inhibitor targeting the disease of hereditary angioedema (HAE). It develops Factor XIIa, an oral inhibitor for the treatment of HAE which is in preclinical trial. In addition, the company is developing an orally disintegrating tablet formulation, including KONFIDENT-KID for pediatric use with HAE; KONFIDENT-S for adolescent and adult patients with type I or type II HAE; and KONFIDENT for a potential oral therapy for HAE attacks. The company is headquartered in Cambridge, Massachusetts.

Remove Ads

KalVista Pharmaceuticals Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
85th Percentile Overall Score

KALV MarketRank™: 

KalVista Pharmaceuticals scored higher than 85% of companies evaluated by MarketBeat, and ranked 166th out of 930 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    KalVista Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.13, and is based on 7 buy ratings, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    KalVista Pharmaceuticals has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

  • Read more about KalVista Pharmaceuticals' stock forecast and price target.
  • Earnings Growth

    Earnings for KalVista Pharmaceuticals are expected to grow in the coming year, from ($3.56) to ($2.90) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of KalVista Pharmaceuticals is -3.06, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of KalVista Pharmaceuticals is -3.06, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    KalVista Pharmaceuticals has a P/B Ratio of 2.29. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

  • Percentage of Shares Shorted

    13.20% of the float of KalVista Pharmaceuticals has been sold short.
  • Short Interest Ratio / Days to Cover

    KalVista Pharmaceuticals has a short interest ratio ("days to cover") of 12.9, which indicates bearish sentiment.
  • Change versus previous month

    Short interest in KalVista Pharmaceuticals has recently increased by 5.42%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    KalVista Pharmaceuticals does not currently pay a dividend.

  • Dividend Growth

    KalVista Pharmaceuticals does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    13.20% of the float of KalVista Pharmaceuticals has been sold short.
  • Short Interest Ratio / Days to Cover

    KalVista Pharmaceuticals has a short interest ratio ("days to cover") of 12.9, which indicates bearish sentiment.
  • Change versus previous month

    Short interest in KalVista Pharmaceuticals has recently increased by 5.42%, indicating that investor sentiment is decreasing significantly.
  • News Sentiment

    KalVista Pharmaceuticals has a news sentiment score of 0.44. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.77 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 15 news articles for KalVista Pharmaceuticals this week, compared to 3 articles on an average week.
  • Search Interest

    Only 2 people have searched for KALV on MarketBeat in the last 30 days. This is a decrease of -33% compared to the previous 30 days.
  • MarketBeat Follows

    Only 2 people have added KalVista Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is a decrease of -33% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, KalVista Pharmaceuticals insiders have bought 1,071.10% more of their company's stock than they have sold. Specifically, they have bought $2,162,146.00 in company stock and sold $184,625.00 in company stock.

  • Percentage Held by Insiders

    10.50% of the stock of KalVista Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Read more about KalVista Pharmaceuticals' insider trading history.
Receive KALV Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for KalVista Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

KALV Stock News Headlines

Brace Yourself for Jeff Bezos’ “Amazon Helios”
Jeff Bezos quietly backing world-changing tech (not AI) The Amazon founder is quietly advancing a radical technology that could change society forever and make early investors rich.
What is Leerink Partnrs' Forecast for KALV Q4 Earnings?
See More Headlines

KALV Stock Analysis - Frequently Asked Questions

KalVista Pharmaceuticals' stock was trading at $8.47 at the beginning of 2025. Since then, KALV stock has increased by 31.6% and is now trading at $11.15.
View the best growth stocks for 2025 here
.

KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) released its earnings results on Thursday, December, 5th. The specialty pharmaceutical company reported ($0.91) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.92) by $0.01.

Shares of KALV stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that KalVista Pharmaceuticals investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Tesla (TSLA), JPMorgan Chase & Co. (JPM), Chevron (CVX) and Netflix (NFLX).

Company Calendar

Last Earnings
12/05/2024
Today
4/01/2025
Fiscal Year End
4/30/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:KALV
Employees
100
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$24.83
High Stock Price Target
$30.00
Low Stock Price Target
$19.00
Potential Upside/Downside
+122.5%
Consensus Rating
Buy
Rating Score (0-4)
3.13
Research Coverage
8 Analysts

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-126,640,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Price / Cash Flow
N/A
Book Value
$4.86 per share
Price / Book
2.30

Miscellaneous

Free Float
44,229,000
Market Cap
$554.83 million
Optionable
Optionable
Beta
0.76

Social Links

The Next 7 Blockbuster Stocks for Growth Investors Cover

Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.

Get This Free Report

This page (NASDAQ:KALV) was last updated on 4/2/2025 by MarketBeat.com Staff
From Our Partners